In vivo, the xenograft tumour model depicted that treatment with TGF-β1 or miR-10b agomir significantly promoted GBM tumour growth, whereas the miR-10b antagomir remarkably inhibited tumour growth, even in the presence of TGF-β1 [84]. This evidence concerns the gene TGFB1 and glioblastoma.